|
Journal of Kidney Cancer and VHL
Number of Followers: 0  Open Access journalISSN (Print) 2203-5826 This journal is no longer being updated because: the publisher no longer provides RSS feeds |
- Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated
Patient with Metastatic Clear Cell Renal Cancer
Authors: Sara Demurtas, Mara Frascaroli, Federico Sottotetti, Alessandro Rametta, Giuseppe Procopio, Laura Deborah Locati
Pages: 1 - 6
Abstract: Clear cell renal carcinoma (ccRCC) can occur in young people and could be associated with an aggressive behavior. While for the first-line treatment in metastatic disease, there is an agreement to rely on an immunotherapy (IO)-based combination regimen, no standard second-line regimens exist. Generally, tyrosine kinase inhibitors (TKIs) are employed, even in sequence, although no trials have demonstrated yet the best succession. Herein, we present the case of a 39-year-old male, with a very aggressive ccRCC with somatic VHL mutation and distant metastases at diagnosis. He was treated with four different lines of therapies, including TKIs, with progressive multiple tumor deposits. Lenvatinib alone as the fifth line was able to induce a remarkable and prolonged tumor shrinkage with manageable toxicities.
Keywords:
